Clinical trials: Recurrent GBM
High Grade Glioma, BRAF V600E
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.
- Conditions
- High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma
- Trial name
- BRAF (NCT03973918)
- Testing
- Encorafenib, Binimetinib, Research Bloods
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma Multiforme of the Brain
Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme
RATIONALE: Current therapies for Glioblastoma Multiforme provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of brain tumors.
- Trial name
- NCT00003474
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Burzynski Research Institute
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
High Grade Glioma
Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma
RATIONALE: Current therapies for children with recurrent/progressive high grade gliomas provide very limited benefit to the patient.
- Trial name
- NCT00003535
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Burzynski Research Institute
Recurrent Glioblastoma
Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma
Increased glucose metabolism is characteristic for solid tumors. Thereby, glucose is important for the generation of ATP, supply of anabolic substrates and defense against reactive oxygen species in tumor cells.
- Trial name
- ERGO2 (NCT01754350)
- Testing
- calorie-restricted ketogenic diet and transient fasting, standard nutrition
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Glioblastoma, Glioma
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.
- Trial name
- KING (NCT01986348)
- Testing
- Selinexor
- Where
- 6 sites in United States, Denmark and 1 more
- Volunteers
- 76 people
- Sponsor
- Karyopharm Therapeutics Inc
Glioblastoma, Gliosarcoma
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Primary objective: To determine the 6-month progression free survival of patients with recurrent glioblastoma multiforme (GBM) treated with Erlotinib plus Sirolimus.
- Trial name
- NCT00672243
- Testing
- Erlotinib + sirolimus
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
This phase II trial is studying how well vorinostat works in treating patients with progressive or recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00238303
- Testing
- vorinostat, conventional surgery
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.
- Conditions
- Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma
- Trial name
- NCT02175745
- Testing
- 18F-fluoro-dihydroxyphenylalanine, Positron emission tomography (PET), Computed tomography (CT)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Erik Mittra
Glioma, High Grade Astrocytoma
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present…
- Conditions
- Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
- Trial name
- NCT01081223
- Testing
- Cancer vaccine plus immune adjuvant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- TVAX Biomedical
Glioblastoma Multiforme, Glioma
Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
Objectives: 1.1 To determine the efficacy, as measured by 6 month progression-free survival, of therapy with thalidomide combined with CPT-11 in the treatment of patients with recurrent and/or progressive malignant gliomas.
- Trial name
- NCT00412542
- Testing
- Thalidomide, CPT-11, MRI Scan
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
RATIONALE: Cediranib Maleate and gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01310855
- Testing
- cediranib maleate, gefitinib
- Where
- 10 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- University College, London
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
This phase II trial studies how well dovitinib works in treating patients with recurrent or progressive glioblastoma. Dovitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01753713
- Testing
- dovitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Manmeet Ahluwalia, MD
Glioblastoma Multiforme
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme.
- Trial name
- NCT00704288
- Testing
- XL184
- Where
- 8 sites in United States
- Volunteers
- 222 people
- Sponsor
- Exelixis
Glioblastoma Multiforme, Anaplastic Glioma
Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
The goal of this clinical research study is to learn if vorinostat when given with isotretinoin and temozolomide can help to control glioblastoma or gliosarcoma. The safety of these drug combinations will also be studied.
- Trial name
- NCT00555399
- Testing
- Vorinostat, Isotretinoin, Surgical Resection
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, Gliosarcoma
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00354913
- Testing
- hydroxyurea, imatinib mesylate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Glioblastoma, Gliosarcoma
BIBF 1120 for Recurrent High-Grade Gliomas
BIBF 1120 is a newly discovered compound that may stop cancer cells from growing abnormally. This drug is currently being used in treatment for other cancers in research studies and information from those other research studies…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01380782
- Testing
- BIBF 1120
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Patrick Y. Wen, MD
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
This phase I/II trial studies the side effects and best dose of temsirolimus when given together with perifosine and to see how well it works in treating patients with recurrent or progressive malignant glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01051557
- Testing
- Laboratory Biomarker Analysis, Perifosine, Temsirolimus
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM.
- Trial name
- NCT03034135
- Testing
- Disulfiram/Copper, Temozolomide (TMZ)
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cantex Pharmaceuticals
Glioblastoma, Glioma
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
This phase II trial will investigate the efficacy and safety of the addition of Optune (Tumor Treating Fields [TTFields] Therapy) to bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma.
- Conditions
- Glioblastoma, Glioma, Gliosarcoma
- Trial name
- NCT02743078
- Testing
- Bevacizumab, TTFields Therapy
- Where
- 11 sites in United States
- Volunteers
- 3 people
- Sponsor
- RTOG Foundation, Inc.